Brief: Jacobio Pharmaceuticals Received Cde Approval For Phase Ii Pivotal Study Of Kras G12c Inhibitor Jab-21822
06/09/2022 02:34
Sept 6 (Reuters) - Jacobio Pharmaceuticals Group Co Ltd
1167.HK :
* RECEIVED CDE APPROVAL FOR PHASE II PIVOTAL STUDY OF KRAS
G12C
INHIBITOR JAB-21822 IN CHINA
Source text for Eikon: ID:
Further company coverage: 1167.HK
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan